QIAGEN (NYSE:QGEN) Expected to Post Earnings of $0.53 Per Share

Wall Street brokerages expect that QIAGEN (NYSE:QGEN) will report earnings of $0.53 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for QIAGEN’s earnings. The lowest EPS estimate is $0.51 and the highest is $0.53. QIAGEN posted earnings of $0.58 per share during the same quarter last year, which suggests a negative year over year growth rate of 8.6%. The company is expected to report its next earnings report on Tuesday, October 26th.

On average, analysts expect that QIAGEN will report full-year earnings of $2.45 per share for the current fiscal year, with EPS estimates ranging from $2.42 to $2.47. For the next financial year, analysts anticipate that the company will report earnings of $2.03 per share, with EPS estimates ranging from $1.95 to $2.13. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for QIAGEN.

QIAGEN (NYSE:QGEN) last announced its quarterly earnings results on Thursday, July 29th. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.01. QIAGEN had a return on equity of 21.31% and a net margin of 21.92%. The company had revenue of $567.31 million during the quarter, compared to analyst estimates of $562.35 million. During the same quarter last year, the firm posted $0.55 earnings per share.

A number of brokerages recently commented on QGEN. Citigroup dropped their price target on QIAGEN from $65.00 to $58.00 and set a “buy” rating for the company in a research note on Wednesday, July 14th. Zacks Investment Research downgraded QIAGEN from a “buy” rating to a “hold” rating and set a $57.00 price objective for the company. in a report on Thursday. Cheuvreux downgraded QIAGEN from a “buy” rating to a “hold” rating and set a $49.53 price objective for the company. in a report on Wednesday, July 14th. Berenberg Bank reiterated a “buy” rating on shares of QIAGEN in a report on Friday, June 11th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of QIAGEN in a report on Thursday, June 17th. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $54.18.

Several institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. boosted its position in QIAGEN by 114.6% in the first quarter. Russell Investments Group Ltd. now owns 369,708 shares of the company’s stock worth $17,836,000 after purchasing an additional 197,412 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in QIAGEN by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 13,595 shares of the company’s stock worth $661,000 after purchasing an additional 1,628 shares during the last quarter. Eversept Partners LP boosted its position in QIAGEN by 35.0% in the first quarter. Eversept Partners LP now owns 454,721 shares of the company’s stock worth $22,140,000 after purchasing an additional 117,859 shares during the last quarter. Sei Investments Co. boosted its position in QIAGEN by 6.6% in the second quarter. Sei Investments Co. now owns 53,184 shares of the company’s stock worth $2,595,000 after purchasing an additional 3,282 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in QIAGEN by 64.5% in the first quarter. Cubist Systematic Strategies LLC now owns 11,799 shares of the company’s stock worth $574,000 after purchasing an additional 4,625 shares during the last quarter. 52.17% of the stock is currently owned by institutional investors.

QGEN stock traded up $0.36 on Monday, reaching $54.70. The company’s stock had a trading volume of 729,348 shares, compared to its average volume of 787,586. The business has a fifty day simple moving average of $52.73 and a two-hundred day simple moving average of $50.16. QIAGEN has a 12-month low of $45.33 and a 12-month high of $59.00. The firm has a market cap of $12.47 billion, a PE ratio of 26.49, a PEG ratio of 1.98 and a beta of 0.21. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.90 and a current ratio of 3.58.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Featured Story: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on QIAGEN (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for QIAGEN (NYSE:QGEN)

Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.